Literature DB >> 29357134

Apelinergic System Structure and Function.

Kyungsoo Shin1, Calem Kenward1, Jan K Rainey1,2.   

Abstract

Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein-coupled receptor named the apelin receptor (AR/APJ/APLNR). Ligand-AR interactions have been implicated in regulation of the adipoinsular axis, cardiovascular system, and central nervous system alongside pathological processes. Each ligand may be processed into a variety of bioactive isoforms endogenously, with apelin ranging from 13 to 55 amino acids and apela from 11 to 32, typically being cleaved C-terminal to dibasic proprotein convertase cleavage sites. The C-terminal region of the respective precursor protein is retained and is responsible for receptor binding and subsequent activation. Interestingly, both apelin and apela exhibit isoform-dependent variability in potency and efficacy under various physiological and pathological conditions, but most studies focus on a single isoform. Biophysical behavior and structural properties of apelin and apela isoforms show strong correlations with functional studies, with key motifs now well determined for apelin. Unlike its ligands, the AR has been relatively difficult to characterize by biophysical techniques, with most characterization to date being focused on effects of mutagenesis. This situation may improve following a recently reported AR crystal structure, but there are still barriers to overcome in terms of comprehensive biophysical study. In this review, we summarize the three components of the apelinergic system in terms of structure-function correlation, with a particular focus on isoform-dependent properties, underlining the potential for regulation of the system through multiple endogenous ligands and isoforms, isoform-dependent pharmacological properties, and biological membrane-mediated receptor interaction. © 2018 American Physiological Society. Compr Physiol 8:407-450, 2018.
Copyright © 2018 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29357134      PMCID: PMC5821487          DOI: 10.1002/cphy.c170028

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  319 in total

1.  C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action.

Authors:  Alexandre Murza; Élie Besserer-Offroy; Jérôme Côté; Patrick Bérubé; Jean-Michel Longpré; Robert Dumaine; Olivier Lesur; Mannix Auger-Messier; Richard Leduc; Philippe Sarret; Éric Marsault
Journal:  J Med Chem       Date:  2015-02-24       Impact factor: 7.446

2.  Activation of Endogenous Cardiac Stem Cells by Apelin-13 in Infarcted Rat Heart.

Authors:  Ning Kun Zhang; Yi Cao; Zhi Ming Zhu; Nan Zheng; Li Wang; Xiao Hong Xu; Lian Ru Gao
Journal:  Cell Transplant       Date:  2016-02-26       Impact factor: 4.064

3.  Effects of apelin on reproductive functions: relationship with feeding behavior and energy metabolism.

Authors:  Suat Tekin; Yavuz Erden; Suleyman Sandal; Ebru Etem Onalan; Fatma Ozyalin; Hasan Ozen; Bayram Yilmaz
Journal:  Arch Physiol Biochem       Date:  2016-08-05       Impact factor: 4.076

4.  Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential.

Authors:  Cathleen Juhl; Sylvia Els-Heindl; Ria Schönauer; Gorden Redlich; Erik Haaf; Frank Wunder; Bernd Riedl; Nils Burkhardt; Annette G Beck-Sickinger; Donald Bierer
Journal:  ChemMedChem       Date:  2016-08-25       Impact factor: 3.466

5.  Apelin increases contractility in failing cardiac muscle.

Authors:  Tieying Dai; Genaro Ramirez-Correa; Wei Dong Gao
Journal:  Eur J Pharmacol       Date:  2006-09-23       Impact factor: 4.432

6.  Cloning, pharmacological characterization and brain distribution of the rat apelin receptor.

Authors:  N De Mota ; Z Lenkei; C Llorens-Cortès
Journal:  Neuroendocrinology       Date:  2000-12       Impact factor: 4.914

7.  Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury.

Authors:  Lauren A O'Donnell; Arpita Agrawal; Praveena Sabnekar; Marc A Dichter; David R Lynch; Dennis L Kolson
Journal:  J Neurochem       Date:  2007-09       Impact factor: 5.372

8.  Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid.

Authors:  Alexandre Murza; Karine Belleville; Jean-Michel Longpré; Philippe Sarret; Éric Marsault
Journal:  Biopolymers       Date:  2014-07       Impact factor: 2.505

9.  Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice.

Authors:  Keiko Higuchi; Takayuki Masaki; Koro Gotoh; Seiichi Chiba; Isao Katsuragi; Katsuhiro Tanaka; Tetsuya Kakuma; Hironobu Yoshimatsu
Journal:  Endocrinology       Date:  2007-03-08       Impact factor: 4.736

10.  Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.

Authors:  Aimee L Brame; Janet J Maguire; Peiran Yang; Alex Dyson; Rubben Torella; Joseph Cheriyan; Mervyn Singer; Robert C Glen; Ian B Wilkinson; Anthony P Davenport
Journal:  Hypertension       Date:  2015-02-23       Impact factor: 10.190

View more
  18 in total

1.  Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients.

Authors:  Florian Gourgue; Françoise Derouane; Cedric van Marcke; Elodie Villar; Helene Dano; Lieven Desmet; Caroline Bouzin; Francois P Duhoux; Patrice D Cani; Bénédicte F Jordan
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

2.  Proapelin is processed extracellularly in a cell line-dependent manner with clear modulation by proprotein convertases.

Authors:  Kyungsoo Shin; Michael Landsman; Stephanie Pelletier; Bader N Alamri; Younes Anini; Jan K Rainey
Journal:  Amino Acids       Date:  2018-11-15       Impact factor: 3.520

Review 3.  The Elabela-APJ axis: a promising therapeutic target for heart failure.

Authors:  Zheng Ma; Juan-Juan Song; Sara Martin; Xin-Chun Yang; Jiu-Chang Zhong
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

4.  Apela improves cardiac and renal function in mice with acute myocardial infarction.

Authors:  Yang Pan; Quanyi Li; Hong Yan; Jin Huang; Zhi Wang
Journal:  J Cell Mol Med       Date:  2020-07-20       Impact factor: 5.310

Review 5.  Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity.

Authors:  Maryam Eskandari Mehrabadi; Roohullah Hemmati; Amin Tashakor; Ahmad Homaei; Masoumeh Yousefzadeh; Karim Hemati; Saman Hosseinkhani
Journal:  Biomed Pharmacother       Date:  2021-02-05       Impact factor: 7.419

6.  The network map of Elabela signaling pathway in physiological and pathological conditions.

Authors:  Shobha Dagamajalu; D A B Rex; G P Suchitha; Akhila B Rai; Jan K Rainey; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2021-08-02       Impact factor: 5.782

7.  A network map of apelin-mediated signaling.

Authors:  Shobha Dagamajalu; D A B Rex; Pushparani Devi Philem; Jan K Rainey; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2021-04-02       Impact factor: 5.782

8.  Increased Elabela levels in the acute ST segment elevation myocardial infarction patients.

Authors:  Yurdaer Dönmez; Armağan Acele
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

Review 9.  The Protective Effects and Mechanisms of Apelin/APJ System on Ischemic Stroke: A Promising Therapeutic Target.

Authors:  Yanjun Tian; Ruijiao Chen; Yunlu Jiang; Bo Bai; Tongju Yang; Haiqing Liu
Journal:  Front Neurol       Date:  2020-03-03       Impact factor: 4.003

10.  Elabela may regulate SIRT3-mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic-induced myocardial injury.

Authors:  Cheng Li; Xiao Miao; Shudong Wang; Yucheng Liu; Jian Sun; Quan Liu; Lu Cai; Yonggang Wang
Journal:  J Cell Mol Med       Date:  2020-11-26       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.